Galmed Pharmaceuticals to Report Second Quarter 2018 Financial Results and Provide Business Update on Thursday, August 2
TEL AVIV, Israel, July 26, 2018 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed? or the "Company"), a clinical-stage biopharmaceutical company focused on the development of the liver targeted SCD1 modulator Aramchol(TM), a once-daily, oral therapy for the treatment of nonalcoholic steatohepatitis, or NASH, announced today that it will host a conference call and webcast on Thursday, August 2, 2018, to provide an update on current developments with respect to its clinical programs for Aramchol(TM) and to discuss financial results for the three and six months ended June 30, 2018.
http://mma.prnewswire.com/media/595923/Galmed_Pharmaceuticals_Ltd_Logo.jpg
Conference Call & Webcast:
Thursday, August 2 @8:30am Eastern Time
Within the US: 888-394-8218
Outside the US: 323-701-0225
From Israel: 1809-212-883
Conference ID: 5856233
Webcast: http://public.viavid.com/index.php?id=130659
Replays, Available through August 16:
Domestic: 844-512-2921
International: 412-317-6671
Replay PIN: 5856233
About Aramchol(TM) and Non-alcoholic Steatohepatitis (NASH)
Aramchol(TM) (arachidyl amido cholanoic acid) is a novel fatty acid bile acid conjugate, inducing beneficial modulation of intra-hepatic lipid metabolism. Aramchol(TM)'s ability to modulate hepatic lipid metabolism was discovered and validated in animal models, demonstrating down regulation of the three key pathologies of NASH; steatosis, inflammation and fibrosis. The effect of AramcholTM on fibrosis is mediated by down regulation of steatosis and directly on human collagen producing cells. Aramchol(TM) has been granted by the FDA Fast Track designation status for the treatment of NASH.
NASH is an emerging world crisis impacting an estimated 3% to 5% of the U.S. population and an estimated 2% to 4% globally. It is the fastest growing cause of liver cancer and liver transplant in the U.S. due to the rise in obesity. NASH is the progressive form of non-alcoholic fatty liver disease that can lead to cardiovascular disease, cirrhosis and liver-related mortality.
About Galmed Pharmaceuticals Ltd.
Galmed is a clinical-stage biopharmaceutical company focused on the development of Aramchol, a first in class, novel, once-daily, oral therapy for the treatment of NASH for variable populations. Galmed recently announced top-line results of the ARREST Study, a multicenter, randomized, double blind, placebo-controlled Phase IIb clinical study designed to evaluate the efficacy and safety of Aramchol in subjects with NASH, who are overweight or obese, and who are pre-diabetic or type-II-diabetic. Galmed is currently preparing for an end of Phase IIb meeting with the FDA to discuss the results of the ARREST Study and a Phase III study protocol, with a view to initiating a Phase III clinical study of Aramchol in 2019.
View original content:http://www.prnewswire.com/news-releases/galmed-pharmaceuticals-to-report-second-quarter-2018-financial-results-and-provide-business-update-on-thursday-august-2-300686942.html
SOURCE Galmed Pharmaceuticals Ltd.
